Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration

This study has been completed.
Information provided by:
Ophthotech Corporation Identifier:
First received: December 4, 2007
Last updated: January 21, 2010
Last verified: January 2010
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2008
  Estimated Primary Completion Date: No date given